Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis
Pooled result · All-cause mortalityResult — go to the resultEstimate 0.47 95% CI 0.33–0.67Authors' conclusion
The use of SGLT2i may be associated with a significant reduction in all-cause mortality and risk of HF hospitalization in actively treated cancer patients with Type 2 diabetes. Our study highlights the need for further investigation through prospective RCTs to confirm the efficacy and safety of SGLT2i in attenuating cardiotoxicity and supporting cardiovascular health in oncology settings.
Study context
- Population
- Cancer patients with type 2 diabetes undergoing chemotherapypatients in 11 observational retrospective studies
- Participants
- 104,327 patients
- Comparison
- Cancer patients with type 2 diabetes undergoing chemotherapy with concomitant use of SGLT2i compared with those not using SGLT2i
- Outcome
- All-cause mortality
Methodological details11 observational retrospective studies
- 11 observational retrospective studies
Pooled result
As reported in the abstract
Estimate
0.47
95% CI 0.33–0.67
P < 0.0001
Further pooled results
| Outcome | Estimate | P value |
|---|---|---|
| HF hospitalizationSignificant reduction with SGLT2i | 0.44 (95% CI 0.27–0.72) | P = 0.001 |
Risk of bias (NIH Quality Assessment Tool)
- Studies at moderate risk of bias
- two
- All other included studies had a low risk of bias
Original publication
Effects of sodium–glucose cotransporter 2 inhibitors in patients with cancer and diabetes mellitus: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. Published 25 April 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →